Colorectal Cancer
Conditions
Keywords
Phase I, Cancer, EGFR, Metastatic Colorectal Cancer, Oncology, RAS/RAF Wild-Type, Nal-IRI, EGFR Inhibitor, Oligoclonal Antibody, Nanoliposome, Nanoliposomal Irinotecan
Brief summary
A phase 1b/2a study evaluating the combination of MM-151 + nal-IRI + 5-FU + Leucovorin in RAS/RAF wild-type Metastatic Colorectal Cancer.
Detailed description
Part 1: Patients will be enrolled to determine the maximum tolerated dose, safety and tolerability of MM-151 + nal-IRI + 5-FU + LV in patients with mCRC that are RAS/RAF wild-type. Part 2: Patients will be enrolled at the maximum tolerated dose of MM-151 in combination with nal-IRI + 5-FU + LV to characterize initial efficacy in conjunction with levels of irinotecan and SN-38 measured in tissue.
Interventions
Sponsors
Merrimack Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must be greater than 18 years of age * Patients must be able to provide informed consent * Patients must have KRAS/NRAS/BRAF wild-type colorectal cancer * Willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 120 days following the last dose of any study therapy). This applies to women of childbearing potential as well as fertile men and their partners
Exclusion criteria
* Patients who have had previous pelvic radiation treatment * Patients who are pregnant or lactating * Patients who have untreated (primary) or uncontrolled Central Nervous System (CNS) (primary or metastatic) malignancies; patients with CNS metastases who have undergone surgery or radiotherapy or who have been on a stable dose of corticosteroids for at least 2 weeks and whose disease is stable prior to the first scheduled day of dosing will be eligible for the trial. * History of any second malignancy in the last 3 years; patients with prior history of in-situ cancer or basal or squamous cell skin cancer are eligible. * Patients who have received other recent antitumor therapy including any standard chemotherapy or radiation within 14 days and bevacizumab within 28 days (and having passed the time of any actual or anticipated toxicities) prior to the first scheduled dose of the study treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To find the phase II dose of MM-151 based on safety and tolerability of MM-151 + nal-IRI + 5-FU + Leucovorin that will be assessed through evaluation of dose limiting toxicity reporting. | The DLT timeframe is from date of first dose up until 42 days after that date |
| To correlate disease response according to RECIST with levels of irinotecan and SN-38 in tumor tissue | 2 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The PK parameters of MM-151 and nal-IRI will be described per AUC | Priming Phase Day 1, Priming Phase Day 8, C1D1, C1D8, C1D15, C1D22, C2D1, C2D15, C2D17, C2D22, C3D1, C5D1 | — |
| Objective response based on RECIST | 2 years | — |
| The number of participants with adverse events (AE) related to treatment with MM-151 + nal-IRI + 5-FU + leucovorin, assessed according to NCI CTCAE v4.0 | 2 years | These will be described by abnormalities in hematology, blood chemistry and other laboratory abnormalities, ECG, physical examination, vital signs and other safety parameters. Frequency, duration and severity of the adverse events according to NCI CTCAE v4.0 will be assessed. |
| Presence of anti-drug antibodies will be assessed | 2 years | — |
| Measure pre-treatment and on-treatment levels of EGFR ligands | 2 years | — |
| The PK parameters of MM-151 and nal-IRI will be described per Cmax | Priming Phase Day 1, Priming Phase Day 8, C1D1, C1D8, C1D15, C1D22, C2D1, C2D15, C2D17, C2D22, C3D1, C5D1 | — |
Outcome results
None listed